{"id":"rivastigmine-memantine","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Nausea"},{"rate":"10-15","effect":"Vomiting"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"10-15","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"2-5","effect":"Syncope"}]},"_chembl":{"chemblId":"CHEMBL807","moleculeType":"Small molecule","molecularWeight":"179.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rivastigmine is a cholinesterase inhibitor that prevents the breakdown of acetylcholine, increasing its availability in the brain to improve cognitive function. Memantine is an NMDA receptor antagonist that reduces excitotoxicity from excess glutamate signaling. Together, they address two different pathological mechanisms in Alzheimer's disease through complementary actions.","oneSentence":"This combination drug enhances acetylcholine levels in the brain while blocking NMDA receptor overactivity to slow cognitive decline in Alzheimer's disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:32.862Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT05564169","phase":"PHASE3","title":"Masitinib in Patients With Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"AB Science","startDate":"2026-06","conditions":"Alzheimer Disease","enrollment":600},{"nctId":"NCT02670161","phase":"PHASE4","title":"Quality Improvement and Practice Based Research in Neurology Using the EMR","status":"ENROLLING_BY_INVITATION","sponsor":"Endeavor Health","startDate":"2016-05","conditions":"Brain Tumors, Epilepsy, Migraine","enrollment":3300},{"nctId":"NCT01872598","phase":"PHASE3","title":"Masitinib in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"AB Science","startDate":"2012-01","conditions":"Alzheimer Disease","enrollment":721},{"nctId":"NCT05321680","phase":"NA","title":"Withdrawal of Antidementia Drugs in Advanced Dementia (WADAD)","status":"COMPLETED","sponsor":"Centro Hospitalar De São João, E.P.E.","startDate":"2021-03-01","conditions":"Dementia","enrollment":16},{"nctId":"NCT05102045","phase":"NA","title":"The Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Istanbul Medipol University Hospital","startDate":"2016-09-01","conditions":"Alzheimer Disease","enrollment":27},{"nctId":"NCT03565809","phase":"","title":"Quality of the Management of Diabetes in Elderly People With Dementia in France","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2017-05-02","conditions":"Alzheimer Disease","enrollment":87816},{"nctId":"NCT03959124","phase":"NA","title":"Deep Brain Stimulation for Alzheimer's Disease","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2020-04-06","conditions":"Alzheimer Disease, Dementia, Alzheimer Type, Deep Brain Stimulation","enrollment":30},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT01677754","phase":"PHASE2","title":"A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-10-24","conditions":"Alzheimer's Disease","enrollment":542},{"nctId":"NCT01362686","phase":"NA","title":"Comparative Research of Alzheimer's Disease Drugs","status":"TERMINATED","sponsor":"Indiana University","startDate":"2011-04","conditions":"Dementia, Alzheimer's Disease","enrollment":200},{"nctId":"NCT00551161","phase":"PHASE4","title":"Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2007-08","conditions":"Alzheimer Disease","enrollment":12},{"nctId":"NCT01696591","phase":"","title":"The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD","status":"UNKNOWN","sponsor":"Duk Lyul Na","startDate":"2012-03","conditions":"Alzheimer Disease, Dementia, Brain Diseases","enrollment":14},{"nctId":"NCT00234637","phase":"PHASE4","title":"Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-11","conditions":"Alzheimer's Disease","enrollment":204},{"nctId":"NCT01025466","phase":"PHASE4","title":"Exelon Patch and Combination With Memantine Comparative Trial","status":"COMPLETED","sponsor":"Inha University Hospital","startDate":"2008-12","conditions":"Alzheimer's Disease","enrollment":206},{"nctId":"NCT00305903","phase":"PHASE4","title":"Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-03","conditions":"Alzheimer's Disease","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rivastigmine, memantine","genericName":"Rivastigmine, memantine","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rivastigmine is a small molecule used to treat conditions such as dementia and Alzheimer's disease. Memantine is also a small molecule, specifically used to treat conditions including dementia and Alzheimer's disease, as indicated by ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}